Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Immunogenic cell death of ovarian cancer cells treated with endoplasmic reticulum stressors and cisplatin
EF 2021-22
Résumé
Ovarian cancer is a deadly disease with limited options for treatment. Typical treatment for ovarian cancer consists of a combination of surgery and chemotherapy with cisplatin (CDDP). While this initial treatment usually results in remission, the cancer often returns, resistant to CDDP. Therefore, novel therapies are needed in these cases. A relatively novel avenue for cancer therapy involves inducing the process of immunogenic cell death (ICD). ICD is a type of cell death that involves the release of danger signals. These danger signals can then act as a vaccine to stimulate the immune system to attack the cancer cells of origin and prevent recurrence of the cancer after its initial remission. While CDDP is toxic to cancer cells, it is incapable of inducing ICD. CDDP kills cancer cells through a traditional cell death mechanism that does not result in the release of danger signals. Therefore, it is possible that combining CDDP with other drugs that are capable of generating ICD could increase CDDP's toxicity to cancer cells and prevent the recurrence of the cancer. Two candidate drugs that could act as ICD inducers are mifepristone and nelfinavir. Both of these drugs have demonstrated the ability to kill ovarian cancer cells, as well as activate some of the cellular pathways that are required for ICD. Therefore, the goal of this project will be to determine if these drugs are capable of inducing ICD, and to determine whether these drugs increase the toxicity of CDDP when used in combination.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
466529
Name
Forgie Benjamin
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Immunogenic cell death of ovarian cancer cells treated with endoplasmic reticulum stressors and cisplatin
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Therpauetics; Cell Death Pathways; Drug Interactions; Endoplasmic Reticulum Stress; Immunogenic Cell Death; Ovarian Cancer
Abstract
Ovarian cancer is a deadly disease with limited options for treatment. Typical treatment for ovarian cancer consists of a combination of surgery and chemotherapy with cisplatin (CDDP). While this initial treatment usually results in remission, the cancer often returns, resistant to CDDP. Therefore, novel therapies are needed in these cases. A relatively novel avenue for cancer therapy involves inducing the process of immunogenic cell death (ICD). ICD is a type of cell death that involves the release of danger signals. These danger signals can then act as a vaccine to stimulate the immune system to attack the cancer cells of origin and prevent recurrence of the cancer after its initial remission. While CDDP is toxic to cancer cells, it is incapable of inducing ICD. CDDP kills cancer cells through a traditional cell death mechanism that does not result in the release of danger signals. Therefore, it is possible that combining CDDP with other drugs that are capable of generating ICD could increase CDDP's toxicity to cancer cells and prevent the recurrence of the cancer. Two candidate drugs that could act as ICD inducers are mifepristone and nelfinavir. Both of these drugs have demonstrated the ability to kill ovarian cancer cells, as well as activate some of the cellular pathways that are required for ICD. Therefore, the goal of this project will be to determine if these drugs are capable of inducing ICD, and to determine whether these drugs increase the toxicity of CDDP when used in combination.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Forgie, Benjamin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~